Special Issue

Advances in Theranostic Radiopharmaceuticals

Message from the Guest Editor

Over the past decade, the field of theranostic radiopharmaceuticals has rapidly expanded to take centre stage in the field of precision medicine. Recent advances in radiochemistry, isotope production, and biology have enabled the translation of increasingly sophisticated radiopharmaceuticals from bench to bedside. At the same time, quantitative imaging, dosimetry, and radiobiology-based modelling are refining our understanding of therapeutic efficacy and safety.

This Special Issue of Pharmaceuticals invites original research papers and comprehensive reviews that highlight innovation in the field of radiotheranostics as well as ongoing challenges. Topics of interest include (but are not limited to) novel radionuclide production methods, advances in radiolabelling methods, new target discovery, and novel radiopharmaceutical development, including in vivo evaluations, clinical translation of novel diagnostic or theranostic radiopharmaceuticals, and investigations of the radiobiology governing theranostic applications. The hope is that this issue will contain contributions that showcase the state-of-the-art and inspire and inform the next generation of radiopharmaceutical innovation.

Guest Editor

Dr. Janke Klevnhans

Department of Pharmaceutical and Pharmacological Sciences, Radiopharmaceutical Research, KU Leuven, Belgium

Deadline for manuscript submissions

31 May 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/259990

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

